Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 5, 2010

View Archived Issues

Eisai reports third quarter 2009 results

Prolor reports topline results from phase I study of CTP-modified human growth hormone

ChemoCentryx initiates phase I clinical trial of CCX-168 for autoimmune diseases

FDA approves Beech Tree's IND for phase I/IIa clinical trial of influenza drug BTL-TML-001

In vivo antiatherosclerotic effects of liver-selective thyromimetic support its clinical evaluation

Figitumumab safe and effective in phase I trial in adrenocortical carcinoma patients

Good safety profile of ciclosporin seen in severe traumatic brain injury patients

Conatus initiates phase II trial of CTS-1027 in combination with Pegasys and Copegus in HCV

Vertex reports preliminary results from phase IIa clinical trial of VX-809 in cystic fibrosis

GlaxoSmithKline discloses new agents for treating Flaviviridae virus infections

Faes Farma discloses novel anti-inflammatory compounds

Swissmedic approves BTG's DigiFab for life-threatening digitalis intoxication

Allergan presents new prostanoid EP2 receptor agonists

FDA accepts for filing Teva's BLA for XM-02 in neutropenia

Nano-sized conjugates with antiangiogenic activity disclosed by Ramot

Novel HDAC inhibitors identified by Karus Therapeutics

Isogenica and Phylogica sign partnership agreement for CIS display and Phylomer peptides

Apeiron and GSK sign agreement for enzyme biotherapeutic APN-01 for ARDS

Compugen discovers CGEN-15001 for treatment of autoimmune disorders

Stem Cell Therapy International and Histostem complete merger

ACT and University of Louisville sign agreement for identification of cancer drug candidates

United Therapeutics and Mondobiotech enter into global strategic partnership for aviptadil

Tanezumab relieves pain in three chronic conditions

Tapentadol IR and ER can be converted to equivalent daily doses

FDA approves Keryx's SPA for phase III X-PECT trial of perifosine in colorectal cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
ASH 2025: Ianalumab data offer break from chronic ITP therapy
BioWorld
Novartis AG’s monoclonal antibody, ianalumab (VAY-736), when added to standard-of-care eltrombopag, extended disease control of primary immune thrombocytopenia...